SuperworthIN8BIO EPS INAB
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$2.06
- Latest quarter, Q2 FY26
- −$0.25
- Fiscal year 2025
- −$4.95
IN8BIO's earnings per share was −$2.06 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.25.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$4.95 | n/a |
| FY2024 | −$18.38 | n/a |
| FY2023 | −$30.60 | n/a |
| FY2022 | −$41.10 | n/a |
| FY2021 | −$71.40 | n/a |
| FY2020 | −$89.70 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.25 | n/a | −$2.06 | |
| Q1 FY26 | −$0.26 | n/a | −$3.05 | |
| Q4 FY25 | −$0.70 | n/a | −$4.95 | |
| Q3 FY25 | −$0.85 | n/a | −$6.63 | |
| Q2 FY25 | −$1.24 | n/a | −$10.27 | |
| Q1 FY25 | −$2.16 | n/a | −$14.54 | |
| Q4 FY24 | −$2.38 | n/a | −$18.38 | |
| Q3 FY24 | −$4.49 | n/a | −$22.60 | |
| Q2 FY24 | −$5.51 | n/a | −$25.01 | |
| Q1 FY24 | −$6.00 | n/a | −$27.60 | |
| Q4 FY23 | −$6.60 | n/a | −$30.60 | |
| Q3 FY23 | −$6.90 | n/a | −$33.60 |
Against its peers
Companies in Healthcare nearest IN8BIO's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| INABIN8BIO | −$2.06 | |
| NEPHNephros | $0.16 | +33% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| ICCCImmucell | $0.08 | −58% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on IN8BIO
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.